Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-08-15

AUTHORS

Verena Schwetz, Rosaria Librizzi, Christian Trummer, Georg Theiler, Claudia Stiegler, Thomas R. Pieber, Barbara Obermayer-Pietsch, Stefan Pilz

ABSTRACT

Previous studies suggest that hyperprolactinaemia might have adverse effects on lipid and glucose metabolism. We therefore aimed to evaluate whether dopamine agonist treatment with cabergoline has significant effects on blood lipids, fasting glucose and HbA1c levels in patients with micro- or macroprolactinoma. In this retrospective observational study the main outcome measures are changes in parameters of glucose and lipid metabolism compared at hyperprolactinaemia and after achievement of normoprolactinaemia by cabergoline treatment. We enrolled 53 study participants (22 females; median [interquartile range] age: 40.0 [27.5 to 50.0] years), 22 (41.5 %) with micro-, and 31 (58.5 %) with macroprolactinomas. After a median follow-up of 9 months, prolactin levels decreased from 220.6 (80.7–913.4) to 11.2 (3.5–18.7) ng/mL (p < 0.001). There was a significant decrease in median levels of low-density lipoprotein (LDL) from 121.6 (±39.4) to 110.6 mg/dl (±37.6, p = 0.005) and total cholesterol from 191 (168.5–241) to 181 mg/dl (162–217, p < 0.001), but no change in high-density lipoprotein (HDL), triglycerides, fasting glucose and HbA1c. We observed a significant increase in testosterone in men and in oestradiol in women. In linear regression analyses using the change in total cholesterol or LDL as dependent, and the change in prolactin, oestradiol, and testosterone as independent variables, no significant predictor of the change in total cholesterol or LDL was identified. In patients with prolactinomas, normalisation of elevated prolactin levels by cabergoline treatment was accompanied by significant reductions in LDL and total cholesterol. Further studies are warranted to confirm our findings and to evaluate the clinical implications of lipid levels in the monitoring and treatment of patients with prolactinomas. More... »

PAGES

155-161

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11011-016-9882-2

DOI

http://dx.doi.org/10.1007/s11011-016-9882-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034492836

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27525431


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cabergoline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dopamine Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ergolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperprolactinemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lipoproteins, HDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pituitary Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prolactinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwetz", 
        "givenName": "Verena", 
        "id": "sg:person.01041066341.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041066341.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Librizzi", 
        "givenName": "Rosaria", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trummer", 
        "givenName": "Christian", 
        "id": "sg:person.01201252150.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201252150.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Feldbach Regional Hospital, Feldbach, Austria", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine, Feldbach Regional Hospital, Feldbach, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Theiler", 
        "givenName": "Georg", 
        "id": "sg:person.01015451477.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015451477.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stiegler", 
        "givenName": "Claudia", 
        "id": "sg:person.01146101363.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146101363.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pieber", 
        "givenName": "Thomas R.", 
        "id": "sg:person.0757263437.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757263437.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Obermayer-Pietsch", 
        "givenName": "Barbara", 
        "id": "sg:person.01071524655.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071524655.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria", 
          "id": "http://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pilz", 
        "givenName": "Stefan", 
        "id": "sg:person.0751717266.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751717266.10"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00745135", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024791870", 
          "https://doi.org/10.1007/bf00745135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11102-010-0277-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008138269", 
          "https://doi.org/10.1007/s11102-010-0277-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/b:pitu.0000004800.57449.67", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023582569", 
          "https://doi.org/10.1023/b:pitu.0000004800.57449.67"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12020-012-9857-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032398967", 
          "https://doi.org/10.1007/s12020-012-9857-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03345636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028831522", 
          "https://doi.org/10.1007/bf03345636"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-08-15", 
    "datePublishedReg": "2016-08-15", 
    "description": "Previous studies suggest that hyperprolactinaemia might have adverse effects on lipid and glucose metabolism. We therefore aimed to evaluate whether dopamine agonist treatment with cabergoline has significant effects on blood lipids, fasting glucose and HbA1c levels in patients with micro- or macroprolactinoma. In this retrospective observational study the main outcome measures are changes in parameters of glucose and lipid metabolism compared at hyperprolactinaemia and after achievement of normoprolactinaemia by cabergoline treatment. We enrolled 53 study participants (22 females; median [interquartile range] age: 40.0 [27.5 to 50.0] years), 22 (41.5\u00a0%) with micro-, and 31 (58.5\u00a0%) with macroprolactinomas. After a median follow-up of 9\u00a0months, prolactin levels decreased from 220.6 (80.7\u2013913.4) to 11.2 (3.5\u201318.7) ng/mL (p\u00a0<\u00a00.001). There was a significant decrease in median levels of low-density lipoprotein (LDL) from 121.6 (\u00b139.4) to 110.6 mg/dl (\u00b137.6, p = 0.005) and total cholesterol from 191 (168.5\u2013241) to 181 mg/dl (162\u2013217, p\u00a0<\u00a00.001), but no change in high-density lipoprotein (HDL), triglycerides, fasting glucose and HbA1c. We observed a significant increase in testosterone in men and in oestradiol in women. In linear regression analyses using the change in total cholesterol or LDL as dependent, and the change in prolactin, oestradiol, and testosterone as independent variables, no significant predictor of the change in total cholesterol or LDL was identified. In patients with prolactinomas, normalisation of elevated prolactin levels by cabergoline treatment was accompanied by significant reductions in LDL and total cholesterol. Further studies are warranted to confirm our findings and to evaluate the clinical implications of lipid levels in the monitoring and treatment of patients with prolactinomas.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11011-016-9882-2", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096554", 
        "issn": [
          "0885-7490", 
          "1573-7365"
        ], 
        "name": "Metabolic Brain Disease", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "keywords": [
      "low-density lipoprotein", 
      "total cholesterol", 
      "high-density lipoprotein", 
      "cabergoline treatment", 
      "prolactin levels", 
      "treatment of hyperprolactinaemia", 
      "dopamine agonist treatment", 
      "retrospective observational study", 
      "elevated prolactin levels", 
      "treatment of patients", 
      "main outcome measures", 
      "parameters of glucose", 
      "blood lipids", 
      "agonist treatment", 
      "observational study", 
      "lipid levels", 
      "outcome measures", 
      "glucose metabolism", 
      "median levels", 
      "linear regression analysis", 
      "patients", 
      "clinical implications", 
      "lipid metabolism", 
      "study participants", 
      "hyperprolactinaemia", 
      "prolactinomas", 
      "cholesterol", 
      "adverse effects", 
      "significant decrease", 
      "significant predictors", 
      "macroprolactinomas", 
      "treatment", 
      "Further studies", 
      "significant increase", 
      "oestradiol", 
      "regression analysis", 
      "significant reduction", 
      "testosterone", 
      "lipoprotein", 
      "dl", 
      "glucose", 
      "metabolism", 
      "normoprolactinaemia", 
      "cabergoline", 
      "previous studies", 
      "levels", 
      "lipids", 
      "triglycerides", 
      "prolactin", 
      "months", 
      "women", 
      "study", 
      "significant effect", 
      "men", 
      "predictors", 
      "changes", 
      "independent variables", 
      "participants", 
      "effect", 
      "findings", 
      "decrease", 
      "normalisation", 
      "measures", 
      "increase", 
      "reduction", 
      "monitoring", 
      "variables", 
      "analysis", 
      "implications", 
      "parameters", 
      "achievement", 
      "micro"
    ], 
    "name": "Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas", 
    "pagination": "155-161", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034492836"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11011-016-9882-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27525431"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11011-016-9882-2", 
      "https://app.dimensions.ai/details/publication/pub.1034492836"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_702.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11011-016-9882-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11011-016-9882-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11011-016-9882-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11011-016-9882-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11011-016-9882-2'


 

This table displays all metadata directly associated to this object as RDF triples.

260 TRIPLES      21 PREDICATES      116 URIs      103 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11011-016-9882-2 schema:about N04df56a0c0ec453ba88d5f07ad721842
2 N0eab22f430dd49ea9bd3bda3cbffb0f9
3 N124a096359a34525b91cd12a39f3ffcd
4 N2c4f08c6133f4575829083bd96b69f42
5 N3399e3667991474597f85de28c2d57bf
6 N3ae1a1601e474208848ce4a841ff7f58
7 N4b943e61dc7b43d6a68d4ac98039df24
8 N6239ea9bc09e40e3a68c18bffc89869e
9 N8c0852aa5ce14930b58d8fe7d0c15358
10 Naed7165aac0e4afeaae4d885d22e7730
11 Nb615b40db8a645d9bc583af0245e7157
12 Nb96c565048a946f4993cefe4f7bafa0d
13 Ndc4556a7561d44cabd775c804e9a6f41
14 Ne50bc2d9ea3142aea017c19f5cc5d70d
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N726e23cf9e394a988e4e5ff91c90f33d
18 schema:citation sg:pub.10.1007/bf00745135
19 sg:pub.10.1007/bf03345636
20 sg:pub.10.1007/s11102-010-0277-9
21 sg:pub.10.1007/s12020-012-9857-y
22 sg:pub.10.1023/b:pitu.0000004800.57449.67
23 schema:datePublished 2016-08-15
24 schema:datePublishedReg 2016-08-15
25 schema:description Previous studies suggest that hyperprolactinaemia might have adverse effects on lipid and glucose metabolism. We therefore aimed to evaluate whether dopamine agonist treatment with cabergoline has significant effects on blood lipids, fasting glucose and HbA1c levels in patients with micro- or macroprolactinoma. In this retrospective observational study the main outcome measures are changes in parameters of glucose and lipid metabolism compared at hyperprolactinaemia and after achievement of normoprolactinaemia by cabergoline treatment. We enrolled 53 study participants (22 females; median [interquartile range] age: 40.0 [27.5 to 50.0] years), 22 (41.5 %) with micro-, and 31 (58.5 %) with macroprolactinomas. After a median follow-up of 9 months, prolactin levels decreased from 220.6 (80.7–913.4) to 11.2 (3.5–18.7) ng/mL (p < 0.001). There was a significant decrease in median levels of low-density lipoprotein (LDL) from 121.6 (±39.4) to 110.6 mg/dl (±37.6, p = 0.005) and total cholesterol from 191 (168.5–241) to 181 mg/dl (162–217, p < 0.001), but no change in high-density lipoprotein (HDL), triglycerides, fasting glucose and HbA1c. We observed a significant increase in testosterone in men and in oestradiol in women. In linear regression analyses using the change in total cholesterol or LDL as dependent, and the change in prolactin, oestradiol, and testosterone as independent variables, no significant predictor of the change in total cholesterol or LDL was identified. In patients with prolactinomas, normalisation of elevated prolactin levels by cabergoline treatment was accompanied by significant reductions in LDL and total cholesterol. Further studies are warranted to confirm our findings and to evaluate the clinical implications of lipid levels in the monitoring and treatment of patients with prolactinomas.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf Nb0e17c475fee44308a4d2a874a18fa4c
29 Nbd94a1a15dce498cb031d16e7d0efa1e
30 sg:journal.1096554
31 schema:keywords Further studies
32 achievement
33 adverse effects
34 agonist treatment
35 analysis
36 blood lipids
37 cabergoline
38 cabergoline treatment
39 changes
40 cholesterol
41 clinical implications
42 decrease
43 dl
44 dopamine agonist treatment
45 effect
46 elevated prolactin levels
47 findings
48 glucose
49 glucose metabolism
50 high-density lipoprotein
51 hyperprolactinaemia
52 implications
53 increase
54 independent variables
55 levels
56 linear regression analysis
57 lipid levels
58 lipid metabolism
59 lipids
60 lipoprotein
61 low-density lipoprotein
62 macroprolactinomas
63 main outcome measures
64 measures
65 median levels
66 men
67 metabolism
68 micro
69 monitoring
70 months
71 normalisation
72 normoprolactinaemia
73 observational study
74 oestradiol
75 outcome measures
76 parameters
77 parameters of glucose
78 participants
79 patients
80 predictors
81 previous studies
82 prolactin
83 prolactin levels
84 prolactinomas
85 reduction
86 regression analysis
87 retrospective observational study
88 significant decrease
89 significant effect
90 significant increase
91 significant predictors
92 significant reduction
93 study
94 study participants
95 testosterone
96 total cholesterol
97 treatment
98 treatment of hyperprolactinaemia
99 treatment of patients
100 triglycerides
101 variables
102 women
103 schema:name Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas
104 schema:pagination 155-161
105 schema:productId N4bd380d051ae4cd7b8c9facb8a1249a3
106 Naa4462d93c024e57a18a3e2fa82edec0
107 Nbeda0bff390144feabcf04cbcb5b661c
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034492836
109 https://doi.org/10.1007/s11011-016-9882-2
110 schema:sdDatePublished 2022-09-02T15:59
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher N625f05d4d19f45b8944736b7f277b2be
113 schema:url https://doi.org/10.1007/s11011-016-9882-2
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N04df56a0c0ec453ba88d5f07ad721842 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Ergolines
119 rdf:type schema:DefinedTerm
120 N0eab22f430dd49ea9bd3bda3cbffb0f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Middle Aged
122 rdf:type schema:DefinedTerm
123 N11d00ceb5dd042e494ea4b95b1479fef rdf:first sg:person.01146101363.97
124 rdf:rest N7e56be46a23a45eba81a99b5bd693bee
125 N124a096359a34525b91cd12a39f3ffcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Adult
127 rdf:type schema:DefinedTerm
128 N1d2e5780d4c04886b7b2df28832e47b7 rdf:first sg:person.0751717266.10
129 rdf:rest rdf:nil
130 N2c4f08c6133f4575829083bd96b69f42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Pituitary Neoplasms
132 rdf:type schema:DefinedTerm
133 N3186434672a14a5db6a089706a9acea1 rdf:first sg:person.01015451477.02
134 rdf:rest N11d00ceb5dd042e494ea4b95b1479fef
135 N3399e3667991474597f85de28c2d57bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Dopamine Agonists
137 rdf:type schema:DefinedTerm
138 N3ae1a1601e474208848ce4a841ff7f58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Female
140 rdf:type schema:DefinedTerm
141 N4b943e61dc7b43d6a68d4ac98039df24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Lipoproteins, HDL
143 rdf:type schema:DefinedTerm
144 N4bd380d051ae4cd7b8c9facb8a1249a3 schema:name dimensions_id
145 schema:value pub.1034492836
146 rdf:type schema:PropertyValue
147 N52cf5fc3f72549faacf83363ce975555 rdf:first Nce6a999c2853453bab40301c0efcf32d
148 rdf:rest N8b3a1bb8adc340a38918804de46197e2
149 N6239ea9bc09e40e3a68c18bffc89869e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Cabergoline
151 rdf:type schema:DefinedTerm
152 N625f05d4d19f45b8944736b7f277b2be schema:name Springer Nature - SN SciGraph project
153 rdf:type schema:Organization
154 N726e23cf9e394a988e4e5ff91c90f33d rdf:first sg:person.01041066341.16
155 rdf:rest N52cf5fc3f72549faacf83363ce975555
156 N7e56be46a23a45eba81a99b5bd693bee rdf:first sg:person.0757263437.98
157 rdf:rest Nb7e6092ad11f47eba14f8b88f2d94679
158 N8b3a1bb8adc340a38918804de46197e2 rdf:first sg:person.01201252150.71
159 rdf:rest N3186434672a14a5db6a089706a9acea1
160 N8c0852aa5ce14930b58d8fe7d0c15358 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Hyperprolactinemia
162 rdf:type schema:DefinedTerm
163 Naa4462d93c024e57a18a3e2fa82edec0 schema:name doi
164 schema:value 10.1007/s11011-016-9882-2
165 rdf:type schema:PropertyValue
166 Naed7165aac0e4afeaae4d885d22e7730 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Cholesterol
168 rdf:type schema:DefinedTerm
169 Nb0e17c475fee44308a4d2a874a18fa4c schema:issueNumber 1
170 rdf:type schema:PublicationIssue
171 Nb615b40db8a645d9bc583af0245e7157 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Humans
173 rdf:type schema:DefinedTerm
174 Nb7e6092ad11f47eba14f8b88f2d94679 rdf:first sg:person.01071524655.82
175 rdf:rest N1d2e5780d4c04886b7b2df28832e47b7
176 Nb96c565048a946f4993cefe4f7bafa0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Prolactinoma
178 rdf:type schema:DefinedTerm
179 Nbd94a1a15dce498cb031d16e7d0efa1e schema:volumeNumber 32
180 rdf:type schema:PublicationVolume
181 Nbeda0bff390144feabcf04cbcb5b661c schema:name pubmed_id
182 schema:value 27525431
183 rdf:type schema:PropertyValue
184 Nce6a999c2853453bab40301c0efcf32d schema:affiliation grid-institutes:grid.11598.34
185 schema:familyName Librizzi
186 schema:givenName Rosaria
187 rdf:type schema:Person
188 Ndc4556a7561d44cabd775c804e9a6f41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Male
190 rdf:type schema:DefinedTerm
191 Ne50bc2d9ea3142aea017c19f5cc5d70d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Treatment Outcome
193 rdf:type schema:DefinedTerm
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
198 schema:name Clinical Sciences
199 rdf:type schema:DefinedTerm
200 sg:journal.1096554 schema:issn 0885-7490
201 1573-7365
202 schema:name Metabolic Brain Disease
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01015451477.02 schema:affiliation grid-institutes:None
206 schema:familyName Theiler
207 schema:givenName Georg
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015451477.02
209 rdf:type schema:Person
210 sg:person.01041066341.16 schema:affiliation grid-institutes:grid.11598.34
211 schema:familyName Schwetz
212 schema:givenName Verena
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01041066341.16
214 rdf:type schema:Person
215 sg:person.01071524655.82 schema:affiliation grid-institutes:grid.11598.34
216 schema:familyName Obermayer-Pietsch
217 schema:givenName Barbara
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071524655.82
219 rdf:type schema:Person
220 sg:person.01146101363.97 schema:affiliation grid-institutes:grid.11598.34
221 schema:familyName Stiegler
222 schema:givenName Claudia
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146101363.97
224 rdf:type schema:Person
225 sg:person.01201252150.71 schema:affiliation grid-institutes:grid.11598.34
226 schema:familyName Trummer
227 schema:givenName Christian
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201252150.71
229 rdf:type schema:Person
230 sg:person.0751717266.10 schema:affiliation grid-institutes:grid.11598.34
231 schema:familyName Pilz
232 schema:givenName Stefan
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751717266.10
234 rdf:type schema:Person
235 sg:person.0757263437.98 schema:affiliation grid-institutes:grid.11598.34
236 schema:familyName Pieber
237 schema:givenName Thomas R.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757263437.98
239 rdf:type schema:Person
240 sg:pub.10.1007/bf00745135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024791870
241 https://doi.org/10.1007/bf00745135
242 rdf:type schema:CreativeWork
243 sg:pub.10.1007/bf03345636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028831522
244 https://doi.org/10.1007/bf03345636
245 rdf:type schema:CreativeWork
246 sg:pub.10.1007/s11102-010-0277-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008138269
247 https://doi.org/10.1007/s11102-010-0277-9
248 rdf:type schema:CreativeWork
249 sg:pub.10.1007/s12020-012-9857-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1032398967
250 https://doi.org/10.1007/s12020-012-9857-y
251 rdf:type schema:CreativeWork
252 sg:pub.10.1023/b:pitu.0000004800.57449.67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023582569
253 https://doi.org/10.1023/b:pitu.0000004800.57449.67
254 rdf:type schema:CreativeWork
255 grid-institutes:None schema:alternateName Department of Internal Medicine, Feldbach Regional Hospital, Feldbach, Austria
256 schema:name Department of Internal Medicine, Feldbach Regional Hospital, Feldbach, Austria
257 rdf:type schema:Organization
258 grid-institutes:grid.11598.34 schema:alternateName Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria
259 schema:name Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria
260 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...